Latest News about JNJ
Recent news which mentions JNJ
Johnson & Johnson Reports Updated Data From Two Early-Stage Multiple Myeloma Studies Of Talvey Combo Treatment
September 27, 2024
From Benzinga
In-Depth Analysis: Johnson & Johnson Versus Competitors In Pharmaceuticals Industry
September 26, 2024
From Benzinga
Why Masimo Stock Crushed the Market Today
September 25, 2024
From Motley Fool
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
September 25, 2024
From Benzinga
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
September 25, 2024
From Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
September 23, 2024
From Benzinga
Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients
September 20, 2024
From Benzinga
Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease
September 20, 2024
From Benzinga
2 Vanguard Index Funds Could Turn $400 Per Month Into $16,800 in Annual Dividend Income by Retirement
September 19, 2024
From Motley Fool
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
September 18, 2024
From Benzinga
Should You Buy Novavax Stock After This Regulatory Win?
September 13, 2024
From Motley Fool
Unpacking the Latest Options Trading Trends in Johnson & Johnson
September 12, 2024
Tickers
JNJ
From Benzinga
Competitor Analysis: Evaluating Johnson & Johnson And Competitors In Pharmaceuticals Industry
September 12, 2024
From Benzinga
How To Earn $500 A Month From Johnson & Johnson Stock
September 12, 2024
From Benzinga
Metals in Tampons: FDA Initiates New Safety Measures and Testing
September 11, 2024
From Benzinga
Sony Music-Universal Music JV Hits Johnson & Johnson With Copyright Lawsuit Over Unlicensed Music Use Covering 80 Videos
September 11, 2024
From Benzinga
Johnson & Johnson's Mid-Stage Lung Cancer Trial Reveals Fewer Infusion-Related Reactions
September 11, 2024
From Benzinga
Is Hims & Hers Health the Next Teladoc?
September 11, 2024
From Motley Fool
2 Stocks That Are Passive Income Machines to Buy and Hold Forever
September 11, 2024
From Motley Fool
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
September 10, 2024
From Benzinga
Kenvue Set To Pop Like A Tylenol Gelcap? Golden Cross Looms On Stock Chart
September 10, 2024
From Benzinga
Dell, CoStar, PayPal And A Major Health Care Stock On CNBC's 'Final Trades'
September 06, 2024
From Benzinga
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
September 06, 2024
From Benzinga
Johnson & Johnson Raises Talc Settlement Offer to $9B, Moves Closer to Settlement Victory
September 05, 2024
From Benzinga
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
September 05, 2024
From Benzinga
2 Dividend Stocks With Payouts That May Not Be as Safe as They Seem
September 05, 2024
From Motley Fool
Court Orders Johnson & Johnson To Compensate Auris Health Shareholders $1B
September 04, 2024
From Benzinga
3 Dividend Stocks to Double Up on Right Now
September 04, 2024
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.